https://www.aigom.it/wp-content/uploads/2025/07/loc24ottobre.png1041742Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-01 08:59:432025-07-01 08:59:43AIGOM-VERONA 24 OTTOBRE 2025-CONVENGNO ECM-CARCINOMA MAMMARIO FARMACI ANTITUMORALI ORALI E SOTTOCUTE: IMPATTO SULLA QUALITA’ DI VITA DEI PAZIENTI E SULL’ORGANIZZAZIONE
https://www.aigom.it/wp-content/uploads/2025/07/ART1LUGLIO.png1146960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-01 08:46:042025-07-01 08:46:04ELIZANENTANT FOR VASOMOTOR SYMPTOMS FROM ENDOCRINE THERAPY FOR BREAST CANCER
https://www.aigom.it/wp-content/uploads/2025/06/ART24.6.png1272888Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-23 08:16:072025-06-23 08:16:07ZOLBETUXIMAB PLUS mFOLFOX6 IN PATIENTS WITH CLDN18.2-positive, HER2-negative, UNTREATED, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA (SPOTLIGHT): A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/06/ART3.6.png1350960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-03 07:58:002025-06-03 07:58:00DATOPOTAMAB DERUXTECAN IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH ACTIONABLE GENOMIC ALTERATIONS: RESULTS FROM THE PHASE II TROPION-Lung05 STUDY.
https://www.aigom.it/wp-content/uploads/2025/05/ART27MAGGIO.png1411960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-27 08:00:382025-05-27 08:00:38PEMBROLIZUMAB AND CHEMOTHERAPY IN HIGH-RISK, EARLY-STAGE, ER+/HER2-BREAST CANCER: A RANDOMIZED PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/05/ART20.5.png1254841Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-20 09:51:122025-05-20 09:51:12DIAGNOSIS AND MANAGEMENT OF INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA: GUIDELINE ENDORSED BY ITALIAN SOCIETY OF INFECTION AND TROPICAL DISEASES (SIMIT), THE ITALIAN SOCIETY OF ANTI-INFECTIVE THERAPY (SITA), THE ITALIAN GROUP FOR ANTIMICROBIAL STEWARDSHIP (GISA), THE ITALIAN ASSOCIATION OF CLINICAL MICROBIOLOGIST (AMCLI) AND THE ITALIAN SOCIETY OF MICROBIOLOGY (SIM).
https://www.aigom.it/wp-content/uploads/2025/05/ART13.5.png1273960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-13 10:38:432025-05-13 10:38:43OlympiA: A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ADJUVANT OLAPARIB AFTER (NEO)ADJUVANT CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA1 AND/OR BRCA2 PATHOGENIC VARIANTS AND HIGH RISK HER2-NEGATIVE PRIMARY BREAST CANCER: LONGER TERM FOLLOW-UP
https://www.aigom.it/wp-content/uploads/2025/05/Screenshot-2025-05-06-102711.png1046752Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-06 09:01:132025-05-16 08:17:26NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 16-SABATO 17 MAGGIO 2025
https://www.aigom.it/wp-content/uploads/2025/05/ART6MAGGIO.png1284923Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-06 08:45:352025-05-06 08:45:35FIRST-LINE MOBOCERTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH EGFR EXON 20 INSERTION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER IN THE PHASE III EXCLAIM-2 TRIAL
https://www.aigom.it/wp-content/uploads/2025/04/Screenshot-2025-04-11-100128-2.png428300Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-04-11 08:12:362025-07-01 08:31:5716 GIUGNO 2025-AIGOM LE NOVITA’ DA CHICAGO 2025: L’EVOLUZIONE DELLE CONOSCENZE IN ONCOLOGIA
